Intsel Chimos

What Intsel Chimos does

Intsel Chimos is a French pharmaceutical exploitant and distributor headquartered in Saint-Cloud, France. Founded in 1966 and currently operating as an SAS under the Farmaxess holding company, it holds Marketing Authorization Holder (exploitant) status under the French Public Health Code (CSP) and serves as the France-based regulatory, distribution, and pharmacovigilance operator for international pharmaceutical companies. Its commercial focus is innovative medicines and orphan drugs targeting patients in therapeutic stalemate with rare or serious diseases, delivered through four integrated service modules: Regulatory Affairs (MA submissions, ANSM/EMA liaison, regulatory intelligence), Logistics and Supply Chain (cold-chain storage at +2/+8°C, +15/+25°C, and frozen, with 24-hour order-to-delivery and real-time tracking), Pharmacovigilance and Quality Assurance (adverse event reporting, GDP/GMP/CSP compliance), and Promotion and Sales (customized sales force deployment for the French market). Supporting products include Compassionate Use (AAC), Early Access Programs (AAP), market access strategy, and clinical trial distribution using electronic data capture (EDC) systems compliant with GDPR.

The company operates a portfolio of over 80 products across multiple therapeutic areas under early access and commercial use, with named international partners including Biophytis, Fennec Pharma, Phaxiam, Pharma&, and Univar. Distribution reaches French hospitals, wholesalers, and community pharmacies (officines). Wholly-owned subsidiaries Diverchim CDMO (organic synthesis and small-batch active ingredient manufacturing, GMP certified since 2015) and Centre Lab (acquired 2018) extend capabilities upstream into API development and adjacent distribution. Technology infrastructure comprises cold-chain logistics systems, real-time shipment tracking, digital inventory management, EDC platforms, and the Chorus public-sector invoicing platform.

Revenue mechanics are transaction-based: Intsel Chimos earns through promoting and distributing partner products (transaction fees on exploitant/MA products), distributing under AAC and AAP frameworks, and providing clinical trial distribution and pharmacovigilance as professional services. Pricing is contractually negotiated rather than publicly disclosed. With approximately 60 employees and Saint-Cloud as its single operating geography, the company functions as a focused, regulation-dependent services operator in the French niche of orphan and early-access pharmaceutical commercialization.

Name

Intsel Chimos

Legal name

INTSEL CHIMOS

Website

https://intselchimos.com

Company type

Private

Founded year

1966

Operating status

Operating

Headcount range

11–50 employees

Short description

Intsel Chimos is a French pharmaceutical exploitant and distributor that imports, holds marketing authorization for, and distributes innovative medicines and orphan drugs for international pharma partners, serving French hospitals, pharmacies, and patients with rare or serious diseases.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution & Market Access Services

NAICS

Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860)

akta.pro primary industry

Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)

Keywords

• Pharmaceutical distribution
• Orphan drugs access
• Early access programs
• Compassionate use medicines
• Pharmaceutical market access

Headquarters

HQ city

Saint-cloud

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Exploitant Laboratory Services: As a pharmaceutical exploitant (Marketing Authorization Holder), Intsel Chimos promotes and distributes products of international pharmaceutical companies in the French and European markets. Revenue generated through commercialization of early access medicines and orphan drugs.
2. Compassionate Use (AAC) Distribution: Distribution of medicines under compassionate use programs for patients with serious or life-threatening diseases outside of clinical trials.
3. Early Access Program (AAP) Distribution: Distribution of innovative medicines under early access programs for patients with serious conditions and rare diseases.
4. Clinical Trial Distribution: Distribution services for investigational products within clinical trials, ensuring timely and compliant delivery.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Intsel Chimos is a French pharmaceutical exploitant (Marketing Authorization Holder) that imports, distributes, and promotes innovative medicines and orphan drugs for patients with rare and/or serious diseases. The company provides integrated services spanning the full product lifecycle, including regulatory affairs, pharmacovigilance, quality assurance, temperature-controlled logistics, and commercialization for international pharmaceutical companies seeking to access the French and European markets.

Product overview

Intsel Chimos operates as a pharmaceutical exploitant company offering an integrated service portfolio spanning the entire product lifecycle for innovative medicines and orphan drugs. The core offering combines four main service modules: Regulatory Affairs (strategic planning, MA submissions, health authority liaison), Logistics & Supply Chain (temperature-controlled storage/distribution, 24-hour delivery), Pharmacovigilance & Quality Assurance (adverse event management, GDP/GMP compliance), and Promotion & Sales (market analysis, sales force, promotional compliance). Supporting these are specialized services for early market access including Compassionate Use (AAC), Early Access Programs (AAP), Market Access strategy, and Clinical Trials & Data Collection using EDC platforms. The company operates a portfolio of over 80 products across various therapeutic areas under Early Access and Commercial Use, with a subsidiary Diverchim CDMO providing active ingredient synthesis and manufacturing services.

Differentiator

Problem solved

Functional benefit

Brands

• Diverchim CDMO: French leader in organic synthesis of original molecules, dedicated to development and manufacturing of Active Ingredients in small quantities for pharmaceutical and cosmetic industries

Products and services

• MA & EAP Operator (Marketing Authorization & Early Access Program Operator)

Quantifiable outcome

• 24-hour order processing and delivery for orders received before 3pm
• +1 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Diverchim CDMOcoreStrategic or Co-development Partner · 1 January 2017French CDMO subsidiary specializing in organic synthesis of original molecules. Over 20 years of expertise in development and manufacturing of Active Ingredients in small quantities (grams to hundreds of kilograms) for pharmaceutical and cosmetic industries. GMP certified since 2015.
• Centre LabcoreStrategic or Co-development Partner · 1 January 2017Acquired by Intsel Chimos in 2017 as part of strategic expansion to strengthen pharmaceutical distribution capabilities.
• BiophytiscoreStrategic or Co-development PartnerInternational pharmaceutical company partnering with Intsel Chimos for market access services in France. Biophytis focuses on developing treatments for age-related diseases.
• UnivarminorStrategic or Co-development PartnerPharmaceutical distribution company collaborating with Intsel Chimos for distribution services in the French market.
• Fennec PharmacoreStrategic or Co-development PartnerPharmaceutical company partnered with Intsel Chimos for market access and distribution of their products in France.
• PhaxiamcoreStrategic or Co-development PartnerPharmaceutical partner for market access services, developing innovative treatments for patients.
• Pharma&minorStrategic or Co-development PartnerInternational pharmaceutical company partnering for French market access and distribution services.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• HRA Pharma: French specialty pharmaceutical company focused on women's health, rare diseases, and OTC products with European distribution. Comparable as a mid-sized French specialty pharma player with exploitant and distribution capabilities.
• Fareva: French pharmaceutical and specialty chemicals manufacturer with integrated CDMO and drug product capabilities serving European markets. Closely aligned with Intsel Chimos's combined exploitant + CDMO model in the French pharmaceutical services landscape.
• Delpharm: French-headquartered pharmaceutical contract development and manufacturing organization offering drug product manufacturing, packaging, and supply services across multiple therapeutic areas. Directly comparable to Intsel Chimos's Diverchim CDMO subsidiary in CDMO scale and French/European market positioning.
• CDM Lavoisier: French CDMO specializing in sterile injectable and liquid pharmaceutical manufacturing for the French and European hospital markets. Directly comparable to Diverchim CDMO and Intsel Chimos's hospital-focused distribution activities.
• Recipharm: European CDMO offering development, manufacturing, and supply of pharmaceutical products across multiple dosage forms and therapeutic areas. Comparable to Intsel Chimos's exploitant/distribution services with a CDMO component, though at significantly larger scale.
• Ethypharm: French specialty pharmaceutical company focused on pain, addiction, and central nervous system therapeutics with in-house manufacturing and licensing partnerships. Comparable to Intsel Chimos as a French specialty pharma player with exploitant and distribution functions.
• Orphan Europe (Recordati Group): European specialty pharmaceutical group focused on orphan drugs and rare disease treatments, with significant French market presence. Comparable to Intsel Chimos's rare disease / orphan drug focus and exploitant-style commercialization model.
• Mayoly Spindler: Independent French pharmaceutical laboratory with portfolio across gastroenterology, dermocosmetics, and specialty therapeutics. Comparable mid-sized French pharma operator with exploitant-style activities and distribution to French healthcare providers.
• Unither Pharmaceuticals: French pharmaceutical CDMO specializing in liquid formulations, sterile unit doses, and Blow-Fill-Seal technology for healthcare and consumer health customers. Closely comparable to Diverchim CDMO's specialized small-batch organic synthesis capability.

Broad incumbents

• Catalent: Global pharmaceutical CDMO and drug delivery solutions provider with broad capabilities across development, manufacturing, and clinical supply. Comparable to Intsel Chimos's combined CDMO plus exploitant/distribution offering but at substantially larger scale and broader geographic reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCp0phscYcmSgF5hHMx4er_A
• LinkedInlinkedin.com/company/intsel-chimos

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intsel Chimos